Editor: What To Know
- Medovate, a dynamic medical device company dedicated to the development and commercialization of innovative medical technologies, and Vygon Group, a group specializing in single-use medical devices, today announce that they have signed an exclusive deal to distribute SAFIRA® (SAFer Injection for Regional Anaesthesia) across 60 countries.
- In addition, it raises the international profile of the UK NHS and its clinicians, who are key stakeholders in Medovate and inventors of the SAFIRA innovation.
- A world-leader in the regional anesthesia arena, it is perfectly placed to ensure SAFIRA – which recently attained EU CE regulatory approval – achieves its maximum reach and potential across Europe and beyond.
October 19, 2020
Medovate, a dynamic medical device company dedicated to the development and commercialization of innovative medical technologies, and Vygon Group, a group specializing in single-use medical devices, today announce that they have signed an exclusive deal to distribute SAFIRA® (SAFer Injection for Regional Anaesthesia) across 60 countries. Vygon will start a phased launch of SAFIRA in Europe at the end of 2020, with other global markets to follow.
Medovate notes SAFIRA, developed in collaboration with UK National Health Service (NHS) clinicians, transforms the technique of Peripheral Nerve Blockade into a one-person procedure, giving the anesthetist full control of the injection at all times. This pioneering technology also improves patient safety by helping reduce the risk of nerve damage, as it prevents anesthetic from being injected at high pressures. Furthermore, economic modelling has shown SAFIRA has the potential to help generate significant time and cost savings in a medical setting.
Amid the current COVID-19 pandemic, the European Society for Regional Anaesthesia (ESRA) has recommended that regional anesthesia be considered whenever surgery is planned for a suspected or confirmed COVID-19 patient. Regional anesthesia preserves respiratory function and avoids aerosolization and the potential for transmission of COVID-19, compared to general anesthesia. By making regional anesthesia a one-person procedure SAFIRA helps hospitals meet these recent recommendations.
Vygon is one of the largest independent French medical device companies. It supplies more than 205 million products globally per year. A world-leader in the regional anesthesia arena, it is perfectly placed to ensure SAFIRA – which recently attained EU CE regulatory approval – achieves its maximum reach and potential across Europe and beyond. Medovate is a medtech company that develops essential new technologies created through its development pipeline of NHS innovations, with a focus on anesthesia, airway, critical care, and surgery.
“This agreement with Vygon marks a significant milestone in the launch of SAFIRA across Europe, the US, and a number of other markets,” said Stuart Thomson, Managing Director, Medovate. “This will help establish Medovate on the world stage as a recognized medical device developer and manufacturer. In addition, it raises the international profile of the UK NHS and its clinicians, who are key stakeholders in Medovate and inventors of the SAFIRA innovation.”
“This is a very exciting partnership for Vygon,” said John Kerridge, Vice President, Anaesthesia & Emergency Business Unit, Vygon. “The SAFIRA technology, in terms of its impact on patient safety and clinical end-user efficiency, is in-line with our overall objective of patient/practitioner-based healthcare solutions. The fact that in the very near future the SAFIRA technology will be available in NRFit format further supports this objective. It will enable us to offer a complete NRFit solution for those markets that demand it.”
NRFit (trademark of GEDSA) devices provide dedicated connectors, compliant with ISO 80369-6. NRFit connectors aim to reduce the risk of wrong route administration of medications associated with Regional Anaesthesia procedures.
It is estimated that ten million regional anesthesia procedures are performed across Europe every year. As the use of regional anesthesia continues to grow steadily across Europe, SAFIRA has the potential to make a significant impact.
